vs
QuidelOrtho Corp（QDEL）与世纪互联（VNET）财务数据对比。点击上方公司名可切换其他公司
QuidelOrtho Corp的季度营收约是世纪互联的1.9倍（$699.9M vs $362.7M），世纪互联净利率更高（-10.7% vs -104.7%，领先94.1%），QuidelOrtho Corp自由现金流更多（$-94.7M vs $-193.1M），过去两年世纪互联的营收复合增速更高（17.4% vs -2.9%）
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
VNET Group即世纪互联，是中国领先的第三方中立数据中心服务商，提供机柜托管、云基础设施、混合云部署及网络管理等解决方案，服务覆盖科技、金融、零售等多领域企业客户，为企业数字化运营提供稳定的算力与网络支撑。
QDEL vs VNET — 直观对比
营收规模更大
QDEL
是对方的1.9倍
$362.7M
净利率更高
VNET
高出94.1%
-104.7%
自由现金流更多
QDEL
多$98.4M
$-193.1M
两年增速更快
VNET
近两年复合增速
-2.9%
损益表 — Q3 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $699.9M | $362.7M |
| 净利润 | $-733.0M | $-38.7M |
| 毛利率 | — | 20.9% |
| 营业利润率 | -100.7% | 0.5% |
| 净利率 | -104.7% | -10.7% |
| 营收同比 | -3.7% | — |
| 净利润同比 | -3583.4% | — |
| 每股收益（稀释后） | $-10.78 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收QDELVNET
| Q3 25 | $699.9M | $362.7M | ||
| Q2 25 | $613.9M | — | ||
| Q1 25 | $692.8M | $309.5M | ||
| Q4 24 | $707.8M | — | ||
| Q3 24 | $727.1M | $302.2M | ||
| Q2 24 | $637.0M | $274.4M | ||
| Q1 24 | $711.0M | $262.9M | ||
| Q4 23 | $742.6M | — |
净利润QDELVNET
| Q3 25 | $-733.0M | $-38.7M | ||
| Q2 25 | $-255.4M | — | ||
| Q1 25 | $-12.7M | $-2.4M | ||
| Q4 24 | $-178.4M | — | ||
| Q3 24 | $-19.9M | $-2.1M | ||
| Q2 24 | $-147.7M | $-1.1M | ||
| Q1 24 | $-1.7B | $-22.0M | ||
| Q4 23 | $7.0M | — |
毛利率QDELVNET
| Q3 25 | — | 20.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 25.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 23.2% | ||
| Q2 24 | — | 21.3% | ||
| Q1 24 | — | 21.6% | ||
| Q4 23 | — | — |
营业利润率QDELVNET
| Q3 25 | -100.7% | 0.5% | ||
| Q2 25 | -29.4% | — | ||
| Q1 25 | 4.7% | 0.1% | ||
| Q4 24 | -14.2% | — | ||
| Q3 24 | 2.1% | 24.5% | ||
| Q2 24 | -18.4% | 0.2% | ||
| Q1 24 | -247.3% | 0.2% | ||
| Q4 23 | 5.4% | — |
净利率QDELVNET
| Q3 25 | -104.7% | -10.7% | ||
| Q2 25 | -41.6% | — | ||
| Q1 25 | -1.8% | -0.8% | ||
| Q4 24 | -25.2% | — | ||
| Q3 24 | -2.7% | -0.7% | ||
| Q2 24 | -23.2% | -0.4% | ||
| Q1 24 | -239.9% | -8.4% | ||
| Q4 23 | 0.9% | — |
每股收益（稀释后）QDELVNET
| Q3 25 | $-10.78 | — | ||
| Q2 25 | $-3.77 | — | ||
| Q1 25 | $-0.19 | — | ||
| Q4 24 | $-2.54 | — | ||
| Q3 24 | $-0.30 | — | ||
| Q2 24 | $-2.20 | — | ||
| Q1 24 | $-25.50 | — | ||
| Q4 23 | $0.11 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.1M | $492.1M |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $2.0B | $890.8M |
| 总资产 | $5.7B | $6.1B |
| 负债/权益比越低杠杆越低 | 1.23× | — |
8季度趋势，按日历期对齐
现金及短期投资QDELVNET
| Q3 25 | $98.1M | $492.1M | ||
| Q2 25 | $151.7M | — | ||
| Q1 25 | $127.1M | $544.3M | ||
| Q4 24 | $98.3M | — | ||
| Q3 24 | $143.7M | $219.5M | ||
| Q2 24 | $107.0M | $247.2M | ||
| Q1 24 | $78.5M | $246.9M | ||
| Q4 23 | $167.3M | — |
总债务QDELVNET
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | $1.2B | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.2B | — | ||
| Q4 23 | $2.3B | — |
股东权益QDELVNET
| Q3 25 | $2.0B | $890.8M | ||
| Q2 25 | $2.8B | — | ||
| Q1 25 | $3.0B | $927.8M | ||
| Q4 24 | $3.0B | — | ||
| Q3 24 | $3.2B | $902.9M | ||
| Q2 24 | $3.2B | $900.6M | ||
| Q1 24 | $3.3B | $895.1M | ||
| Q4 23 | $5.0B | — |
总资产QDELVNET
| Q3 25 | $5.7B | $6.1B | ||
| Q2 25 | $6.4B | — | ||
| Q1 25 | $6.5B | $5.4B | ||
| Q4 24 | $6.4B | — | ||
| Q3 24 | $6.8B | $4.3B | ||
| Q2 24 | $6.7B | $4.0B | ||
| Q1 24 | $6.7B | $3.9B | ||
| Q4 23 | $8.6B | — |
负债/权益比QDELVNET
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | 1.28× | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.68× | — | ||
| Q4 23 | 0.45× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-45.5M | $113.8M |
| 自由现金流经营现金流 - 资本支出 | $-94.7M | $-193.1M |
| 自由现金流率自由现金流/营收 | -13.5% | -53.2% |
| 资本支出强度资本支出/营收 | 7.0% | 84.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-153.1M | $-589.7M |
8季度趋势，按日历期对齐
经营现金流QDELVNET
| Q3 25 | $-45.5M | $113.8M | ||
| Q2 25 | $-46.8M | — | ||
| Q1 25 | $65.6M | $27.0M | ||
| Q4 24 | $63.7M | — | ||
| Q3 24 | $117.9M | $108.3M | ||
| Q2 24 | $-97.9M | $55.8M | ||
| Q1 24 | $-700.0K | $37.1M | ||
| Q4 23 | $80.4M | — |
自由现金流QDELVNET
| Q3 25 | $-94.7M | $-193.1M | ||
| Q2 25 | $-84.3M | — | ||
| Q1 25 | $9.4M | $-220.0M | ||
| Q4 24 | $16.5M | — | ||
| Q3 24 | $71.4M | $-95.0M | ||
| Q2 24 | $-133.2M | $-81.6M | ||
| Q1 24 | $-66.8M | $-102.2M | ||
| Q4 23 | $31.8M | — |
自由现金流率QDELVNET
| Q3 25 | -13.5% | -53.2% | ||
| Q2 25 | -13.7% | — | ||
| Q1 25 | 1.4% | -71.1% | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 9.8% | -31.4% | ||
| Q2 24 | -20.9% | -29.8% | ||
| Q1 24 | -9.4% | -38.9% | ||
| Q4 23 | 4.3% | — |
资本支出强度QDELVNET
| Q3 25 | 7.0% | 84.6% | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 8.1% | 79.8% | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 6.4% | 67.3% | ||
| Q2 24 | 5.5% | 50.1% | ||
| Q1 24 | 9.3% | 53.0% | ||
| Q4 23 | 6.5% | — |
现金转化率QDELVNET
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 11.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
VNET
暂无分部数据
